GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Even of there’s an MoA justification for thrombomodulin + antithrombin combination therapy in DIC, it’s a risky proposition from a business standpoint until there are phase-3 data for one or both drugs as a standalone agent. The problem with combination testing at an earlier stage is that a safety problem could end up tainting both drug programs even if each drug is perfectly safe on its own.

Further down the road, combination testing might make sense, however. Regards, Dew